+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Generalized Myasthenia Gravis (gMG) - Market Insights, Epidemiology, and Market Forecast to 2028

  • ID: 4827861
  • Drug Pipelines
  • August 2019
  • Region: Global
  • 215 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Alexion Pharmaceuticals
  • Argenx
  • Catalyst Pharmaceuticals
  • CuraVac
  • Immunovant
  • Momenta Pharmaceuticals
  • MORE
‘Generalized Myasthenia Gravis (gMG)-Market Insights, Epidemiology, and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of gMG in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, and the current and forecasted market size of Generalized Myasthenia Gravis (gMG) from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Generalized Myasthenia Gravis (gMG)-Disease Understanding and Treatment Algorithm
The’s Generalized Myasthenia Gravis (gMG) market report gives a thorough understanding of the Myasthenia Gravis by including details, such as disease definition, classification, symptoms, etiology, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Myasthenia Gravis in the US, Europe, and Japan.

Generalized Myasthenia Gravis (gMG) Epidemiology
The Generalized Myasthenia Gravis (gMG) epidemiology division provide insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Generalized Myasthenia Gravis (gMG) in the 7MM. The epidemiology is segmented by total diagnosed prevalent cases, auto-antibodies specific cases [Anti-AchR Ab (+ve), Anti-MuSK Ab (+ve), Double seronegative] covering the US, EU5 countries (Germany, Spain, Italy, France, and the UK) and Japan from 2017–2028.

According to the author, total diagnosed prevalent population of Generalized Myasthenia Gravis (gMG) in seven major markets was found to be 58,828 in 2017. The estimates suggest a higher diagnosed prevalence of gMG in the United States with 32,188 cases in 2017. Among EU5, Spain had the highest diagnosed prevalent population of Gmg, whereas France had the lowest cases.

Generalized Myasthenia Gravis (gMG) Drug Chapters
This segment of the Generalized Myasthenia Gravis (gMG) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, the therapeutic market size of Generalized Myasthenia Gravis (gMG) is mainly accounted by symptomatic treatments comprising acetylcholinesterase Inhibitors (Mestinon), short-term immunosuppressants (corticosteroids), long-term immunosuppressants (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab, tacrolimus), rapid-acting short-term immunomodulators (intravenous immunoglobulin, plasma exchange), and procedures (thymectomy).

Recently, Soliris (Eculizumab) (Alexion Pharmaceuticals) got approval for MG treatment in 2017. This monoclonal antibody (MAB) is used for preventing acetylcholine receptor antibodies from affecting muscle cells and is helpful for patients resistant to the other available therapies, it has significantly impacted the market size of Myasthenia Gravis after its launch.

Generalized Myasthenia Gravis (gMG) Market Outlook
The Generalized Myasthenia Gravis (gMG) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the author, the market of Generalized Myasthenia Gravis in 7MM was found to be USD 2,602 million in 2017. The United States accounts for the largest market size of Generalized Myasthenia Gravis, in comparison to EU5 (Germany, France, Italy, Spain, and the UK), and Japan.

This market is further expected to grow during the forecasted period of 2019–2028 owing to the launch of upcoming therapies. Detailed chapter for upcoming therapies, like Rozanolixizumab (UCB Pharma); CFZ533 (Novartis); Efgartigimod (Argenx); Zilucoplan (Ra Pharmaceuticals); Firdapse (Catalyst Pharmaceuticals); Hizentra (CSL Behring); Ravulizumab (Alexion Pharmaceuticals); IMVT-1401 (Immunovant); M281 (Momenta Pharmaceuticals); CV-MGO1(CuraVac), and others have also been covered in the report, are expected to enter the MG market by 2028. The market is further divided based on the available and upcoming drugs in to first and second-line of therapies.

Generalized Myasthenia Gravis (gMG) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Generalized Myasthenia Gravis (gMG) Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Generalized Myasthenia Gravis (gMG) Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Generalized Myasthenia Gravis (gMG) Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving the Myasthenia Gravis market.
  • Organize sales and marketing efforts by identifying the best opportunities for Generalized Myasthenia Gravis (gMG) market.
  • To understand the future market competition in the Generalized Myasthenia Gravis (gMG) market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alexion Pharmaceuticals
  • Argenx
  • Catalyst Pharmaceuticals
  • CuraVac
  • Immunovant
  • Momenta Pharmaceuticals
  • MORE
1. Key Insights

2. Generalized Myasthenia Gravis Market Overview at a Glance
2.1. Market Share (%) Distribution of gMG in 2017
2.2. Market Share (%) Distribution of gMG in 2028

3. Disease Overview: Generalized Myasthenia Gravis
3.1. Introduction
3.2. Types of Myasthenia Gravis
3.2.1. Ocular Myasthenia Gravis
3.2.2. Generalized Myasthenia Gravis
3.3. MGFA Classification of Myasthenia Gravis
3.4. Etiology
3.5. Risk Factors
3.6. Signs and Symptoms
3.7. Comorbid conditions in MG
3.8. Genetic Basis of Generalized Myasthenia Gravis
3.9. Pathophysiology of Generalized Myasthenia Gravis
3.9.1. Autoantibodies
3.9.2. Complement cascade
3.10. Biomarkers in Generalized Myasthenia Gravis
3.11. Diagnosis
3.11.1. Differential Diagnosis
3.11.2. Japanese diagnostic criteria for Myasthenia Gravis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Total Diagnosed Prevalent Patient Population of Generalized Myasthenia Gravis
4.4. Country Wise-Epidemiology of Myasthenia Gravis
4.5. United States
4.5.1. Assumptions and Rationale
4.5.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in the US
4.5.3. Autoantibodies- Specific Cases of Generalized Myasthenia Gravis in the US
4.6. Germany
4.6.1. Assumptions and Rationale
4.6.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Germany
4.6.3. Autoantibodies-specific Cases of Generalized Myasthenia Gravis in Germany
4.7. France
4.7.1. Assumptions and Rationale
4.7.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in France
4.7.3. Autoantibodies-specific Cases of Generalized Myasthenia Gravis in France
4.8. Italy
4.8.1. Assumptions and Rationale
4.8.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Italy
4.8.3. Autoantibodies-specific Cases of Generalized Myasthenia Gravis in Italy
4.9. Spain
4.9.1. Assumptions and Rationale
4.9.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Spain
4.9.3. Autoantibodies-specific Cases of Generalized Myasthenia Gravis in Spain
4.10. United Kingdom
4.10.1. Assumptions and Rationale
4.10.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in the United Kingdom
4.10.3. Autoantibodies-specific Cases of Generalized Myasthenia Gravis in the UK
4.11. Japan
4.11.1. Assumptions and Rationale
4.11.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Japan
4.11.3. Autoantibodies-specific Cases of Generalized Myasthenia Gravis in Japan

5. Current Treatment Practices
5.1. International Consensus Guidance for Management of Myasthenia Gravis
5.2. Italian recommendations for the diagnosis and treatment of myasthenia gravis
5.3. German Neurological Society Guidelines for myasthenia gravis
5.4. Japanese Clinical Guidelines for Myasthenia Gravis

6. Unmet Needs

7. Marketed drugs
7.1. Key cross competition- Marketed drugs
7.2. Soliris: Alexion Pharmaceuticals
7.2.1. Drug Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Clinical Development
7.2.5. Safety and Efficacy
7.2.6. Product Profile
7.3. Mestinon: Valeant Pharmaceuticals
7.3.1. Drug Description
7.3.2. Regulatory Milestones
7.3.3. Advantages & Disadvantages
7.3.4. Safety and Efficacy
7.3.5. Product Profile
7.4. Prograf: Astellas Pharma
7.4.1. Drug Description
7.4.2. Regulatory Milestones
7.4.3. Clinical Development
7.4.4. Safety and Efficacy
7.4.5. Product Profile
7.5. Venoglobulin IH: Mitsubishi Tanabe Pharma
7.5.1. Drug Description
7.5.2. Regulatory Milestones
7.5.3. Advantages & Disadvantages
7.5.4. Clinical Development
7.5.5. Product Profile

8. Emerging Therapies
8.1. Key cross competition- Emerging Therapies
8.2. Firdapse: Catalyst Pharmaceuticals
8.2.1. Product Description
8.2.2. Other Development Activities
8.2.3. Clinical Development
8.2.4. Safety and Efficacy
8.2.5. Product Profile
8.3. Hizentra: CSL Behring
8.3.1. Product Description
8.3.2. Other Development Activities
8.3.3. Clinical Development
8.3.4. Safety and Efficacy
8.3.5. Product Profile
8.4. Rozanolixizumab: UCB Pharma
8.4.1. Product Description
8.4.2. Other Development Activities
8.4.3. Clinical Development
8.4.4. Safety and Efficacy
8.4.5. Product Profile
8.5. Efgartigimod : Argenx
8.5.1. Product Description
8.5.2. Other Development Activities
8.5.3. Clinical Development
8.5.4. Safety and Efficacy
8.5.5. Product Profile
8.6. Zilucoplan: Ra Pharmaceuticals
8.6.1. Product Description
8.6.2. Other Development Activities
8.6.3. Clinical Development
8.6.4. Safety and Efficacy
8.6.5. Product Profile
8.7. Ravulizumab: Alexion Pharmaceuticals
8.7.1. Product Description
8.7.2. Clinical Development
8.7.3. Product Profile
8.8. IMVT-1401: Immunovant
8.8.1. Product Description
8.8.2. Other Developmental Activities
8.8.3. Clinical Development
8.8.4. Safety and Efficacy
8.8.5. Product Profile
8.9. M281: Momenta Pharmaceuticals
8.9.1. Product Description
8.9.2. Clinical Development
8.9.3. Safety and Efficacy
8.9.4. Product Profile
8.10. CV-MG01: CuraVac
8.10.1. Product Description
8.10.2. Other Developmental Activities
8.10.3. Clinical Development
8.10.4. Safety and Efficacy
8.10.5. Product Profile
8.11. IGIV-C: Grifols Therapeutics
8.11.1. Product Description
8.11.2. Other Development Activities
8.11.3. Clinical Development
8.11.4. Product Profile
8.12. CFZ533: Novartis
8.12.1. Product Description
8.12.2. Clinical Development
8.12.3. Product Profile

9. Generalized Myasthenia Gravis: 7 Major Market Analysis
9.1. Key Findings
9.2. Market Size of Generalized Myasthenia Gravis in 7MM
9.3. Market Outlook by Country
9.4. The United States: Market Outlook
9.4.1. United States Market Size
9.4.2. Total Market Size of Generalized Myasthenia Gravis
9.4.3. Market Size of Generalized Myasthenia Gravis by First-Line Therapies
9.4.4. Market Size of Generalized Myasthenia Gravis by Second-Line Therapies
9.5. EU-5 Countries: Market Outlook
9.6. Germany
9.6.1. Total Market Size of Generalized Myasthenia Gravis
9.6.2. Market Size of Generalized Myasthenia Gravis by First-Line Therapies
9.6.3. Market Size of Generalized Myasthenia Gravis by Second-Line Therapies
9.7. France
9.7.1. Total Market Size of Generalized Myasthenia Gravis
9.7.2. Market Size of Generalized Myasthenia Gravis by First-Line Therapies
9.7.3. Market Size of Generalized Myasthenia Gravis by Second-Line Therapies
9.8. Italy
9.8.1. Total Market Size of Generalized Myasthenia Gravis
9.8.2. Market Size of Generalized Myasthenia Gravis by First-Line Therapies
9.8.3. Market Size of Generalized Myasthenia Gravis by Second-Line Therapies
9.9. Spain
9.9.1. Total Market Size of Generalized Myasthenia Gravis
9.9.2. Market Size of Generalized Myasthenia Gravis by First-Line Therapies
9.9.3. Market Size of Generalized Myasthenia Gravis by Second-Line Therapies
9.10. United Kingdom
9.10.1. Total Market Size of Generalized Myasthenia Gravis
9.10.2. Market Size of Generalized Myasthenia Gravis by First-Line Therapies
9.10.3. Market Size of Generalized Myasthenia Gravis by Second-Line Therapies
9.11. Japan: Market Outlook
9.11.1. Total Market Size of Generalized Myasthenia Gravis
9.11.2. Market Size of Generalized Myasthenia Gravis by First-Line Therapies
9.11.3. Market Size of Generalized Myasthenia Gravis by Second-Line Therapies

10. Market Drivers

11. Market Barriers

12. Appendix

13. Report Methodology

14. Capabilities

15. Disclaimer

16. About the Author

17. Disclaimer

List of Tables
Table 1: Osserman and Genkins Classification of Myasthenia Gravis, modified by the MGFA/Task Force
Table 2: Summary of the tests used in the diagnosis of myasthenia gravis
Table 3: Proposed diagnostic criteria for myasthenia gravis - Japanese Treatment guidelines
Table 4: Diagnosed Prevalent Patient Population of Generalized Myasthenia Gravis in 7MM (2017–2028)
Table 5: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in the United States (2017–2028)
Table 6: Autoantibodies-specific cases of Myasthenia Gravis in the United States (2017–2028)
Table 7: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Germany (2017–2028)
Table 8: Autoantibodies-specific cases of Generalized Myasthenia Gravis in Germany (2017–2028)
Table 9: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in France (2017–2028)
Table 10: Autoantibodies-specific cases of Generalized Myasthenia Gravis in France (2017–2028)
Table 11: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Italy (2017–2028)
Table 12: Autoantibodies-specific cases of Generalized Myasthenia Gravis in Italy (2017–2028)
Table 13: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Spain (2017–2028)
Table 14: Autoantibodies-specific cases of Generalized Myasthenia Gravis in Spain (2017–2028)
Table 15: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in the UK (2017–2028)
Table 16: Autoantibodies-specific cases of Generalized Myasthenia Gravis in the UK (2017–2028)
Table 17: Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Japan (2017–2028)
Table 18: Autoantibodies-specific cases of Generalized Myasthenia Gravis in Japan (2017–2028)
Table 19: Classification of MG severity and response to therapy
Table 20: Japanese Clinical Guidelines for Myasthenia Gravis
Table 21: Japanese Treatment Strategies for Myasthenia Gravis
Table 22: Key cross competition- Marketed drugs
Table 23: Eculizumab, Clinical Trial Description, 2019
Table 24: Tacrolimus, Clinical Trial Description, 2018
Table 25: GB-0998, Clinical Trial Description, 2018
Table 26: Key cross competition - Emerging Therapies Phase III
Table 27: Key cross competition - Emerging Therapies Phase II
Table 28: Amifampridine Phosphate, Clinical Trial Description, 2019
Table 29: Hizentra, Clinical Trial Description, 2019
Table 30: UCB7665, Clinical Trial Description, 2019
Table 31: Efgartigimod, Clinical Trial Description, 2019
Table 32: RA101495, Clinical Trial Description, 2019
Table 33: RA101495, Clinical Trial Description, 2019
Table 34: IMVT-1401, Clinical Trial Description, 2019
Table 35: M281, Clinical Trial Description, 2019
Table 36: CV-MG01, Clinical Trial Description, 2019
Table 37: IGIV-C, Clinical Trial Description, 2019
Table 38: CFZ533, Clinical Trial Description, 2018
Table 39: 7 Major Market Size of Generalized Myasthenia Gravis in USD Million (2017–2028)
Table 40: United States Market Size of Generalized Myasthenia Gravis in USD Million (2017–2028)
Table 41: Market Size of gMG by First-Line Therapies in USD Million (2017–2028)
Table 42: US gMG Market size by Second Line Therapies in USD Million (2017–2028)
Table 43: Germany Market Size of Generalized Myasthenia Gravis in USD Million (2017–2028)
Table 44: Market Size of gMG by First-Line Therapies in USD Million (2017–2028)
Table 45: Germany gMG Market size by Second Line Therapies in USD Million (2017–2028)
Table 46: France Market Size of Generalized Myasthenia Gravis in USD Million (2017–2028)
Table 47: Market Size of gMG by First-Line Therapies in USD Million (2017–2028)
Table 48: France gMG Market size by Second Line Therapies in USD Million (2017–2028)
Table 49: Italy, Market Size of Generalized Myasthenia Gravis in USD Million (2017–2028)
Table 50: Market Size of gMG by First-Line Therapies in USD Million (2017–2028)
Table 51: Italy gMG Market size by Second Line Therapies in USD Million (2017–2028)
Table 52: Spain, Market Size of Generalized Myasthenia Gravis in USD Million (2017–2028)
Table 53: Market Size of gMG by First-Line Therapies in USD Million (2017–2028)
Table 54: Spain gMG Market size by Second Line Therapies in USD Million (2017–2028)
Table 55: UK Market Size of Generalized Myasthenia Gravis in USD Million (2017–2028)
Table 56: Market Size of gMG by First-Line Therapies in USD Million (2017–2028)
Table 57: UK gMG Market size by Second Line Therapies in USD Million (2017–2028)
Table 58: Japan, Market Size of Generalized Myasthenia Gravis in USD Million (2017–2028)
Table 59: Market Size of gMG by First-Line Therapies in USD Million (2017–2028)
Table 60: Japan gMG Market size by Second Line Therapies in USD Million (2017–2028)

List of Figures
Figure 1: Transmission of Nerve Impulses to Muscles
Figure 2: Signs and Symptoms of Generalized Myasthenia Gravis
Figure 3: Various Components of the Neuromuscular Junction involved in MG
Figure 4: Various Components of the Neuromuscular Junction involved in MG
Figure 5: Pathophysiology of MG at the neuromuscular junction
Figure 6: Complement cascade
Figure 7: Diagnostic testing in myasthenia gravis
Figure 8: Diagnosis flowchart for MG
Figure 9: Diagnosed Prevalent Patient Population of Generalized Myasthenia Gravis in 7MM (2017–2028)
Figure 10: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in the United States (2017–2028)
Figure 11: Autoantibodies-specific cases of Myasthenia Gravis in the US (2017–2028)
Figure 12: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Germany (2017–2028)
Figure 13: Autoantibodies-specific cases of Generalized Myasthenia Gravis in Germany (2017–2028)
Figure 14: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in France (2017–2028)
Figure 15: Autoantibodies-specific cases of Generalized Myasthenia Gravis in France (2017–2028)
Figure 16: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Italy (2017–2028)
Figure 17: Autoantibodies-specific cases of Generalized Myasthenia Gravis in Italy (2017–2028)
Figure 18: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Spain (2017–2028)
Figure 19: Autoantibodies-specific cases of Generalized Myasthenia Gravis in Spain (2017–2028)
Figure 20: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in the UK (2017–2028)
Figure 21: Autoantibodies-specific cases of Generalized Myasthenia Gravis in the UK (2017–2028)
Figure 22: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Japan (2017–2028)
Figure 23: Autoantibodies-specific cases of Generalized Myasthenia Gravis in Japan (2017–2028)
Figure 24: Treatment of Generalized Myasthenia Gravis
Figure 25: Treatment of Severe Myasthenia Gravis Exacerbations
Figure 26: Treatment flow chart: generalized myasthenia
Figure 27: Treatment options for MG - German Neurological Society Guidelines
Figure 28: Treatment strategies for MG
Figure 29: Treatment algorithms for chronic MG and acute MG exacerbations
Figure 30: Unmet Needs for Generalized Myasthenia Gravis
Figure 31: 7 Major Market Size of Generalized Myasthenia Gravis in USD Million (2017–2028)
Figure 32: Market Size of Generalized Myasthenia Gravis in the United States, USD Millions (2017–2028)
Figure 33: Market Size of gMG by First-Line Therapies in USD Million (2017–2028)
Figure 34: US gMG Market size by Second Line Therapies in USD Million (2017–2028)
Figure 35: Market Size of Generalized Myasthenia Gravis in Germany, USD Millions (2017–2028)
Figure 36: Market Size of gMG by First-Line Therapies in USD Million (2017–2028)
Figure 37: Germany gMG Market size by Second Line Therapies in USD Million (2017–2028)
Figure 38: Market Size of Generalized Myasthenia Gravis in France, USD Millions (2017–2028)
Figure 39: Market Size of gMG by First-Line Therapies in USD Million (2017–2028)
Figure 40: France gMG Market size by Second Line Therapies in USD Million (2017–2028)
Figure 41: Market Size of Generalized Myasthenia Gravis in Italy, USD Millions (2017–2028)
Figure 42: Market Size of gMG by First-Line Therapies in USD Million (2017–2028)
Figure 43: Italy gMG Market size by Second Line Therapies in USD Million (2017–2028)
Figure 44: Market Size of Generalized Myasthenia Gravis in Spain, USD Millions (2017–2028)
Figure 45: Market Size of gMG by First-Line Therapies in USD Million (2017–2028)
Figure 46: Spain gMG Market size by Second Line Therapies in USD Million (2017–2028)
Figure 47: Market Size of Generalized Myasthenia Gravis in the UK, USD Millions (2017–2028)
Figure 48: Market Size of gMG by First-Line Therapies in USD Million (2017–2028)
Figure 49: UK gMG Market size by Second Line Therapies in USD Million (2017–2028)
Figure 50: Market Size of Generalized Myasthenia Gravis in Japan, USD Millions (2017–2028)
Figure 51: Market Size of gMG by First-Line Therapies in USD Million (2017–2028)
Figure 52: Japan gMG Market size by Second Line Therapies in USD Million (2017–2028)
Figure 53: Market Drivers
Figure 54: Market Barriers
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Alexion Pharmaceuticals
  • Valeant Pharmaceuticals
  • Astellas Pharma
  • Mitsubishi Tanabe Pharma
  • Catalyst Pharmaceuticals
  • CSL Behring
  • UCB Pharma
  • Argenx
  • Ra Pharmaceuticals
  • Alexion Pharmaceuticals
  • Immunovant
  • Momenta Pharmaceuticals
  • CuraVac
  • Grifols Therapeutics
  • Novartis
Note: Product cover images may vary from those shown
Adroll
adroll